JP2015504081A5 - - Google Patents

Download PDF

Info

Publication number
JP2015504081A5
JP2015504081A5 JP2014552655A JP2014552655A JP2015504081A5 JP 2015504081 A5 JP2015504081 A5 JP 2015504081A5 JP 2014552655 A JP2014552655 A JP 2014552655A JP 2014552655 A JP2014552655 A JP 2014552655A JP 2015504081 A5 JP2015504081 A5 JP 2015504081A5
Authority
JP
Japan
Prior art keywords
alkyl
independently
different
phenyl
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014552655A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015504081A (ja
JP6128133B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/051097 external-priority patent/WO2013110585A1/en
Publication of JP2015504081A publication Critical patent/JP2015504081A/ja
Publication of JP2015504081A5 publication Critical patent/JP2015504081A5/ja
Application granted granted Critical
Publication of JP6128133B2 publication Critical patent/JP6128133B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014552655A 2012-01-23 2013-01-22 Igf−1r/ir阻害剤としての5,8−ジヒドロ−6h−ピラゾロ[3,4−h]キナゾリン Active JP6128133B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12152193.4 2012-01-23
EP12152193 2012-01-23
PCT/EP2013/051097 WO2013110585A1 (en) 2012-01-23 2013-01-22 5, 8 -dihydro- 6h- pyrazolo [3, 4 -h] quinazolines as igf-lr/lr inhibitors

Publications (3)

Publication Number Publication Date
JP2015504081A JP2015504081A (ja) 2015-02-05
JP2015504081A5 true JP2015504081A5 (enExample) 2016-03-10
JP6128133B2 JP6128133B2 (ja) 2017-05-17

Family

ID=47605520

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014552655A Active JP6128133B2 (ja) 2012-01-23 2013-01-22 Igf−1r/ir阻害剤としての5,8−ジヒドロ−6h−ピラゾロ[3,4−h]キナゾリン

Country Status (7)

Country Link
US (1) US9150578B2 (enExample)
EP (1) EP2807166B1 (enExample)
JP (1) JP6128133B2 (enExample)
AR (1) AR089776A1 (enExample)
TW (1) TW201343648A (enExample)
UY (1) UY34586A (enExample)
WO (1) WO2013110585A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017002544A (es) * 2014-09-02 2017-07-19 Pf Medicament Derivados de isoquinolinona utiles en el tratamiento contra el cancer.
US10414769B2 (en) 2015-05-13 2019-09-17 Boehringer Ingelheim International Gmbh 5,8-dimethyl-9-phenyl-5,8-dihydro-6H-pyrazolo[3,4-h]quinazolin-2-yl)-(1H-pyrazol-3-yl)-amines as IGF-1R/IR inhibitors
ES2923415T3 (es) * 2017-08-11 2022-09-27 Shengke Pharmaceuticals Jiangsu Ltd Compuesto de 1H-pirazolo[4,3-H]quinazolina que sirve como inhibidor de proteína quinasa
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
BR112022002698A2 (pt) 2019-08-14 2022-07-19 Incyte Corp Compostos de imidazolil pirimidinilamina como inibidores de cdk2
AU2020364007A1 (en) 2019-10-11 2022-04-28 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CA3243695A1 (en) * 2022-02-04 2023-08-10 Retune Pharma Inc CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND PROCESSES
WO2024153237A1 (zh) * 2023-01-19 2024-07-25 北京普祺医药科技股份有限公司 一种igf-1r酪氨酸激酶抑制剂、药物组合物及其用途
WO2024153226A1 (zh) * 2023-01-19 2024-07-25 北京普祺医药科技股份有限公司 一种吡唑并环类化合物、药物组合物及其用途
CN116458513A (zh) * 2023-05-08 2023-07-21 广东方中高新材料有限公司 一种含镓配合物的咪鲜胺增效水乳制剂及其制备方法
CN116473073A (zh) * 2023-05-08 2023-07-25 广东方中高新材料有限公司 一种含镓配合物的吡唑醚菌酯增效悬浮制剂及其制备方法
CN116473077B (zh) * 2023-05-08 2025-04-11 广东方中高新材料有限公司 一种n,n配位的镓配合物抗菌剂的合成和应用
TW202509078A (zh) 2023-07-07 2025-03-01 美商維里迪恩醫療股份有限公司 治療慢性甲狀腺眼病之方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6825190B2 (en) 2001-06-15 2004-11-30 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
AU2003286895A1 (en) 2002-11-05 2004-06-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of jak and other protein kinases
US7482354B2 (en) * 2003-05-22 2009-01-27 Nerviano Medical Sciences S.R.L. Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
US20050075358A1 (en) 2003-10-06 2005-04-07 Carboni Joan M. Methods for treating IGF1R-inhibitor induced hyperglycemia
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
ES2361782T3 (es) * 2006-05-11 2011-06-22 Irm Llc Compuesto y composiciones como inhibidores de proteína quinasa.
US8735386B2 (en) * 2010-07-23 2014-05-27 Boehringer Ingelheim International Gmbh Aminopyrazoloquinazolines

Similar Documents

Publication Publication Date Title
JP2015504081A5 (enExample)
JP2017527532A5 (enExample)
JP2015078230A5 (enExample)
JP2017510610A5 (enExample)
MX385054B (es) Piridinas sustituidas con heteroarilo y metodos de uso.
WO2014209841A3 (en) Compounds for treating spinal muscular atrophy
JP2016515561A5 (enExample)
JP2015516427A5 (enExample)
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
MX389697B (es) Nuevos derivados de pirazolopirimidina.
JP2014221779A5 (enExample)
JP2015537020A5 (enExample)
TN2017000467A1 (en) Amido-substituted cyclohexane derivatives
JP2013032389A5 (enExample)
JP2014511892A5 (enExample)
JP2014500296A5 (enExample)
JP2013523614A5 (enExample)
JP2016523955A5 (enExample)
WO2014147021A3 (en) 3-acetylamino-1-(phenyl-heteroaryl-aminocarbonyl or phenyl-heteroaryl-carbonylamino)benzene derivatives for the treatment of hyperproliferative disorders
JP2015527333A5 (enExample)
JP2014129360A5 (enExample)
EP4467549A3 (en) Intermediates of n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives
JP2016531871A5 (enExample)
WO2015021396A3 (en) Tricyclic benzoxaborole compounds and uses thereof
EA202090978A1 (ru) Новые макроциклические производные, способ их получения и содержащие их фармацевтические композиции